[Chronic myeloid leukemia. State of the art, May 1993].
New developments in relation to chronic myelogenous leukemia (CML) are characterized by progress in knowledge of pathogenesis, diagnostic improvement such as nosology of Philadelphia-negative CML and diagnosis of minimal residual disease by molecular techniques, advances in drug therapy with hydroxyurea or interferon alpha, and progress in bone marrow transplantation through availability of unrelated donors. In addition, the recognition of suitable prognostic parameters indicates that risk adapted therapy may become possible.
Hehlmann
R
R
III. Medizinische Klinik, Klinikum Mannheim, Universität Heidelberg.
D016026:Bone Marrow Transplantation / Q000379:methods; D003131:Combined Modality Therapy; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000628:therapy*; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000175:diagnosis; D016133:Polymerase Chain Reaction; D011379:Prognosis; D014184:Transplantation, Homologous
D016898:Interferon-alpha; D006918:Hydroxyurea
Die chronisch myeloische Leukämie. "State of the art", Mai 1993.